Kimberly Clark Corp vs Synopsys, Inc. — how do they compare? Kimberly Clark Corp trades at $97.59 (market cap $32.51B), while Synopsys, Inc. trades at $509.99 (market cap $95.39B). The key difference: Synopsys, Inc. is far larger — about 2.9× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays a 5.24% dividend while Synopsys, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 93 Days and Synopsys, Inc. for 71 Days on average.
| KMB | SNPS | |
|---|---|---|
Market Cap | $32.51B | $95.39B |
Volume | 6,139,913 | 3,374,903 |
Sector | Consumer Staples | Technology |
52-Week High | $121.44 | $534.56 |
52-Week Low | $93.05 | $367.70 |
Typical Hold Time | 93 Days | 71 Days |
Enterprise Value | $38.07B | $102.62B |
Dividend Yield | 5.24% | — |
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $97.59, up 1.15% on the day, but remains in a bearish technical trend. The stock has shown mixed earnings performance, beating estimates in Q4 2025 and Q1 2026 but missing in Q2 2026, with revenue declining to $16.45 billion in 2025. The company maintains a strong dividend history, recently declaring a $1.28 payout, while navigating its pending acquisition of Kenvue and executive transitions.
KMB offers a high dividend yield near 5%, supported by 54 consecutive years of increases, but faces risks from the Kenvue integration and cash flow pressures. Analyst consensus is a 'Hold' with a $117.25 price target, suggesting moderate upside. Key risks include execution of the large acquisition and sustaining dividend payouts amid fluctuating cash flows.
Synopsys (SNPS) trades at $509.99, up 1.46% today, and is near its 52-week high. The stock exhibits a bullish technical trend with strong moving average support. Recent quarterly earnings have consistently beaten estimates, and the company's Investor Day in October 2026 highlighted transformative AI partnerships with OpenAI and Amazon, driving a 13% stock surge and upward revisions to long-term revenue guidance.
The outlook is positive, supported by robust analyst sentiment (93% buy ratings) and a consensus price target of $572.54. Key opportunities include AI-driven growth in chip design software and margin expansion from the Ansys acquisition. Risks involve high valuation multiples and integration execution challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →